Medicure Sales And Marketing Effort Underway Following Aggrastat Acquisition
This article was originally published in The Pink Sheet Daily
Executive Summary
Merck separately acquires the right of first refusal for a combination of Aggrastat and Medicure’s investigational cardio-protective compound, the firm says.
You may also be interested in...
Novamed In-Licenses Products from Iroko and EUSA To Strengthen Cardiovascular And Oncology Pipeline
SHANGHAI - NovaMed Pharmaceuticals announced July 10 it has reached agreements with U.S.-based Iroko and U.K. firm EUSA Pharma to in-license Iroko's cardiovascular drugAggrastat (tirofiban) and EUSA's oncology drug Erwinase (crisantaspase)
MGI Purchase Of Guilford Will Create Two-Product Acute Care Sales Force
Reps will target surgeons and anesthesiologists to promote Aloxi post-operative nausea treatment and the pipeline sedative Aquavan. The $177.5 mil. merger is expected to close in the fourth quarter.
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.